Clinical Presentation, Outcomes, and Treatment of Membranous Nephropathy after Transplantation
There are scarce data about clinical presentation and outcomes of posttransplant membranous nephropathy (MN), and few reports include a large number of patients. This was a retrospective cohort including adult patients with posttransplant MN transplanted between 1983 and 2015 in a single center (n=4...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2018/3720591 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849684239726936064 |
|---|---|
| author | Artur Q. B. da Silva Taina V. de Sandes-Freitas Juliana B. Mansur Jose Osmar Medicina-Pestana Gianna Mastroianni-Kirsztajn |
| author_facet | Artur Q. B. da Silva Taina V. de Sandes-Freitas Juliana B. Mansur Jose Osmar Medicina-Pestana Gianna Mastroianni-Kirsztajn |
| author_sort | Artur Q. B. da Silva |
| collection | DOAJ |
| description | There are scarce data about clinical presentation and outcomes of posttransplant membranous nephropathy (MN), and few reports include a large number of patients. This was a retrospective cohort including adult patients with posttransplant MN transplanted between 1983 and 2015 in a single center (n=41). Only patients with histological diagnosis of MN in kidney grafts were included. Clinical and laboratory presentation, histological findings, treatment, and outcomes were detailed. Patients were predominantly male (58.5%), with a mean age of 49.4 ± 13.2 years; 15 were considered as recurrent primary MN; 3 were class V lupus nephritis; 14 were considered as de novo cases, 7 secondary and 7 primary MN; and 9 cases were considered primary but it was not possible to distinguish between de novo MN and recurrence. Main clinical presentations were proteinuria (75.6%) and graft dysfunction (34.1%). Most patients with primary recurrent and de novo primary MN were submitted to changes in maintenance immunosuppressive regimen, but no standard strategy was identified; 31 patients presented partial or complete remission, and glomerulopathy appeared not to impact graft and patient survival. |
| format | Article |
| id | doaj-art-bde9770397274ce2a02bb63af07a04a6 |
| institution | DOAJ |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-bde9770397274ce2a02bb63af07a04a62025-08-20T03:23:31ZengWileyInternational Journal of Nephrology2090-214X2090-21582018-01-01201810.1155/2018/37205913720591Clinical Presentation, Outcomes, and Treatment of Membranous Nephropathy after TransplantationArtur Q. B. da Silva0Taina V. de Sandes-Freitas1Juliana B. Mansur2Jose Osmar Medicina-Pestana3Gianna Mastroianni-Kirsztajn4Federal University of São Paulo (UNIFESP), São Paulo, SP, BrazilFederal University of Ceará (UFC), Fortaleza, CE, BrazilFederal University of São Paulo (UNIFESP), São Paulo, SP, BrazilFederal University of São Paulo (UNIFESP), São Paulo, SP, BrazilFederal University of São Paulo (UNIFESP), São Paulo, SP, BrazilThere are scarce data about clinical presentation and outcomes of posttransplant membranous nephropathy (MN), and few reports include a large number of patients. This was a retrospective cohort including adult patients with posttransplant MN transplanted between 1983 and 2015 in a single center (n=41). Only patients with histological diagnosis of MN in kidney grafts were included. Clinical and laboratory presentation, histological findings, treatment, and outcomes were detailed. Patients were predominantly male (58.5%), with a mean age of 49.4 ± 13.2 years; 15 were considered as recurrent primary MN; 3 were class V lupus nephritis; 14 were considered as de novo cases, 7 secondary and 7 primary MN; and 9 cases were considered primary but it was not possible to distinguish between de novo MN and recurrence. Main clinical presentations were proteinuria (75.6%) and graft dysfunction (34.1%). Most patients with primary recurrent and de novo primary MN were submitted to changes in maintenance immunosuppressive regimen, but no standard strategy was identified; 31 patients presented partial or complete remission, and glomerulopathy appeared not to impact graft and patient survival.http://dx.doi.org/10.1155/2018/3720591 |
| spellingShingle | Artur Q. B. da Silva Taina V. de Sandes-Freitas Juliana B. Mansur Jose Osmar Medicina-Pestana Gianna Mastroianni-Kirsztajn Clinical Presentation, Outcomes, and Treatment of Membranous Nephropathy after Transplantation International Journal of Nephrology |
| title | Clinical Presentation, Outcomes, and Treatment of Membranous Nephropathy after Transplantation |
| title_full | Clinical Presentation, Outcomes, and Treatment of Membranous Nephropathy after Transplantation |
| title_fullStr | Clinical Presentation, Outcomes, and Treatment of Membranous Nephropathy after Transplantation |
| title_full_unstemmed | Clinical Presentation, Outcomes, and Treatment of Membranous Nephropathy after Transplantation |
| title_short | Clinical Presentation, Outcomes, and Treatment of Membranous Nephropathy after Transplantation |
| title_sort | clinical presentation outcomes and treatment of membranous nephropathy after transplantation |
| url | http://dx.doi.org/10.1155/2018/3720591 |
| work_keys_str_mv | AT arturqbdasilva clinicalpresentationoutcomesandtreatmentofmembranousnephropathyaftertransplantation AT tainavdesandesfreitas clinicalpresentationoutcomesandtreatmentofmembranousnephropathyaftertransplantation AT julianabmansur clinicalpresentationoutcomesandtreatmentofmembranousnephropathyaftertransplantation AT joseosmarmedicinapestana clinicalpresentationoutcomesandtreatmentofmembranousnephropathyaftertransplantation AT giannamastroiannikirsztajn clinicalpresentationoutcomesandtreatmentofmembranousnephropathyaftertransplantation |